Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies

被引：0

作者：

Yosipovitch, Gil ^{[1
]}

Staender, Sonja ^{[2
]}

Metz, Martin ^{[3
]}

Pink, Andrew E. ^{[4
]}

Silverberg, Jonathan, I ^{[5
]}

Sofen, Howard ^{[6
]}

Ahmed, Faiz ^{[7
]}

Noda, Aliene ^{[8
]}

Lopez, Zarif K. Jabbar ^{[8
]}

Piketty, Christophe ^{[8
]}

Kwatra, Shawn G. ^{[9
,10
]}

机构：

[1] Univ Miami, Miami Itch Ctr, Miller Sch Med, Miami, FL USA

[2] Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany

[3] Charite, Inst Allergol, Berlin, Germany

[4] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England

[5] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[6] UCLA, Sch Med, Dept Med Dermatol, Los Angeles, CA USA

[7] Galderma Labs, Dallas, TX USA

[8] Galderma R&D, Zug, Switzerland

[9] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD USA

[10] Univ Maryland, Maryland Itch Ctr, Sch Med, Baltimore, MD USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

efficacy; nemolizumab; prurigo nodularis; pruritus; safety; TRIAL;

D O I：

10.1093/bjd/ljae266.046

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

672

引用

页码：47 / 48

页数：2

共 50 条

[21] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Blauvelt, Andrew
Tsai, Tsen-Fang
Langley, Richard G.
Miller, Megan
Shen, Yaung-Kaung
You, Yin
Yang, Ya-Wen
Papp, Kim A.
Puig, Luis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 827 - 834
[22] Dual Bronchodilation With QVA149 Improves Dyspnea in Patients With Moderate-to-Severe COPD: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies
Mahler, Donald
Larbig, Michael
Patalano, Francesco
Maitra, Samopriyo
Banerji, Donald
CHEST, 2015, 148 (04)
[23] Indacaterol/glycopyrrolate Improves Dyspnea In Us Patients With Moderate-To-Severe COPD: A Subgroup Analysis Of The Pooled Flight1 And Flight2 Studies
Mahler, D. A.
Maitra, S.
Fogel, R.
Banerji, D.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
[24] Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2)
Nappi, Rossella E.
Johnson, Kimball A.
Stute, Petra
Blogg, Martin
English, Marci
Morga, Antonia
Scrine, Ludmila
Siddiqui, Emad
Ottery, Faith D.
MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2024, 31 (06): : 512 - 521
[25] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
Bissonnette, R.
Fernandez-Penas, P.
Puig, L.
Peserico, A.
Fumero, E.
Mendelsohn, A.
Rozzo, S.
Menter, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47
[26] Efficacy and safety of lebrikizumab at 16 weeks: pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis
Warren, Richard B.
Silverberg, Jonathan I.
Guttman-Yassky, Emma
Thaci, Diamant
Irvine, Alan
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric L.
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Garcia Gil, Esther
Seneschal, Julien
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[27] Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and-2 trials
Bauer, Andrea
Schuttelaar, Marie-Louise
Baranowski, Keith
Plohberger, Ursula
Sorensen, Laura
Worm, Margitta
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[28] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
McMichael, Amy
Desai, Seemal R.
Qureshi, Aamir
Rastogi, Shipra
Alexis, Andrew F.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 267 - 276
[29] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
Amy McMichael
Seemal R. Desai
Aamir Qureshi
Shipra Rastogi
Andrew F. Alexis
American Journal of Clinical Dermatology, 2019, 20 : 267 - 276
[30] Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
Kimball, Alexa Boer
Nikai, Enkeleida
Zhu, Baojin
Carlier, Hilde
Yosipovitch, Gil
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S19 - S19

← 1 2 3 4 5 →